VANCOUVER, BC, March 19, 2024 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, announced that since March 1, 2024 it has shipped its botanical psilocybin drug candidate, PEX010, to four countries for clinical trials at leading research institutions. PEX010 will be studied in Canada, the United States, Belgium, and Israel, for…
Opinion | ‘The Phenomenon Itself Isn’t New’: What We Heard This Week
“The term ‘administrative harm’ is relatively new … but the phenomenon itself isn’t new.” — Marisha Burden, MD, MBA, of the University of Colorado School
July 15, 2024